DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes

  • Santarpia L
  • Iwamoto T
  • Di Leo A
  • et al.
73Citations
Citations of this article
61Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

DNA repair pathways can enable tumor cells to survive DNA damage induced by chemotherapy and thus provide prognostic and/or predictive value. We evaluated Affymetrix gene expression profiles for 145 DNA repair genes in untreated breast cancer (BC) patients (n = 684) and BC patients treated with regimens containing neoadjuvant taxane/anthracycline (n = 294) or anthracycline (n = 210). We independently assessed estrogen receptor (ER)-positive/HER2-negative, HER2-positive, and ER-negative/HER2-negative subgroups for differential expression, bimodal distribution, and the prognostic and predictive value of DNA repair gene expression. Twenty-two genes were consistently overexpressed in ER-negative tumors, and five genes were overexpressed in ER-positive tumors, but no differences in expression were associated with HER2 status. In ER-positive/HER2-negative tumors, the expression of nine genes (BUB1, FANCI, MNAT1, PARP2, PCNA, POLQ, RPA3, TOP2A, and UBE2V2) was associated with poor prognosis, and the expression of one gene (ATM) was associated with good prognosis. Furthermore, the prognostic value of specific genes did not correlate with proliferation. A few genes were associated with chemotherapy response in BC subtypes and treatment-specific manner. In ER-negative/HER2-negative tumors, the MSH2, MSH6, and FAN1 (previously MTMR15) genes were associated with pathological complete response and residual invasive cancer in taxane/anthracycline-treated patients. Conversely, PMS2 expression was associated with residual invasive cancer in treatments using anthracycline as a single agent. In HER2-positive tumors, TOP2A was associated with patient response to anthracyclines but not to taxane/anthracycline regimens. In genes expressed in a bimodal fashion, RECQL4 was significantly associated with clinical outcome. In vitro studies showed that defects in RECQL4 impair homologous recombination, sensitizing BC cells to DNA-damaging agents.

References Powered by Scopus

Comprehensive molecular portraits of human breast tumours

9502Citations
N/AReaders
Get full text

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

9223Citations
N/AReaders
Get full text

Gene expression profiling predicts clinical outcome of breast cancer

8181Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes

133Citations
N/AReaders
Get full text

Human DNA polymerase θ grasps the primer terminus to mediate DNA repair

113Citations
N/AReaders
Get full text

Molecular mechanism of anti-cancer activity of phycocyanin in triple-negative breast cancer cells

95Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Santarpia, L., Iwamoto, T., Di Leo, A., Hayashi, N., Bottai, G., Stampfer, M., … Bianchini, G. (2013). DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes. The Oncologist, 18(10), 1063–1073. https://doi.org/10.1634/theoncologist.2013-0163

Readers over time

‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘2505101520

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 18

53%

Researcher 12

35%

Professor / Associate Prof. 3

9%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 22

51%

Biochemistry, Genetics and Molecular Bi... 14

33%

Agricultural and Biological Sciences 6

14%

Pharmacology, Toxicology and Pharmaceut... 1

2%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 1

Save time finding and organizing research with Mendeley

Sign up for free
0